Avalo Therapeutics, Inc. (AVTX) Stock Forecast
AVTX analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.86 / 5 from 14 analysts
- Price target
- $44.08 average of analyst targets
- Upside to target
- +291.2% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.63
- 52-week range
- $11.27 – $22.87
AVTX analyst ratings
14 analystsNumber of analysts at each rating.
AVTX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
AVTX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.56 | −$0.66 | −$0.45 | −$2.19 | +74.3% | 8 |
| Current fiscal year (2026) | −$2.73 | −$3.06 | −$2.18 | −$5.84 | +53.3% | 8 |
| Next fiscal year (2027) | −$2.71 | −$4.10 | −$1.33 | −$2.73 | +0.7% | 10 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
AVTX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 11 |
| Current fiscal year (2026) | $0 | $0 | $0 | −100.0% | 12 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 12 |
AVTX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
AVTX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.55 | −$0.55 | −$0.56 | −$0.56 | −$0.56 | +2.1% | 3 up · 2 down |
| Current fiscal year (2026) | −$2.56 | −$2.56 | −$2.72 | −$2.72 | −$2.73 | +6.7% | 3 up · 4 down |
| Next fiscal year (2027) | −$2.76 | −$2.76 | −$2.74 | −$2.74 | −$2.71 | −2.0% | 3 up · 4 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
AVTX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; AVTX beat in 6 of 12.
What analysts expect from AVTX
14 analysts cover Avalo Therapeutics; their consensus rating is strong buy (4.86 on a 1–5 scale, where 5 is a strong buy). The average price target is $44.08, 291.2% above the latest close of $11.27. Analysts expect earnings of −$2.73 per share for 2026, +53.3% from a year earlier. For 2027 the average estimate is −$2.71 per share. Avalo Therapeutics beat the EPS estimate in 6 of the last 12 quarters.
Related: AVTX income statement, AVTX key metrics, AVTX chart. See the AVTX stock overview for the latest quote and news.
AVTX forecast FAQ
What is Avalo Therapeutics's price target?
The average analyst price target for Avalo Therapeutics is $44.08, 291.2% above the latest close of $11.27.
Is Avalo Therapeutics a buy, hold or sell?
Of 14 analysts covering Avalo Therapeutics, 12 rate it a strong buy, 2 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Avalo Therapeutics's EPS forecast?
Analysts forecast −$2.73 per share for 2026 (range −$3.06 to −$2.18); for 2027 the estimate is −$2.71.
When does Avalo Therapeutics report earnings?
Avalo Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026; the EPS estimate is $-0.63.
Does Avalo Therapeutics usually beat earnings estimates?
Avalo Therapeutics reported EPS at or above the analyst estimate in 6 of the last 12 quarters.